Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial ...Middle East

PRINCETON, N.J. and SUZHOU, China, April 8, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, and...

Hence then, the article about transcenta announces collaboration with agilent to develop a claudin18 2 companion diagnostic to support osemitamab tst001 global phase iii trial was published today ( Tuesday 09/04/2024 - 04:13 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial )

Also on site :

• PIN Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Pinterest, Inc.
• Sheena Easton, 66, Is Still a Stunning Redhead Several Years After Leaving the Chaos of Mega-Fame Behind
• ‘Murphy Brown’ Star Jessie Jones Dead at 75